The challenges of adherence and persistence with iron chelation therapy

International Journal of Hematology

Volumn 94, Issue 5, 2011, Pages 453-460

  Porter, John B ^a   Evangeli, Michael ^b   El Beshlawy, Amal ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Adherence; Iron chelation therapy; Persistence

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE;

AGE; ANEMIA; BLOOD TRANSFUSION; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; DEPRESSION; DRUG HALF LIFE; ECONOMIC ASPECT; EDUCATIONAL STATUS; GENDER; GEOGRAPHY; HOSPITALIZATION; HUMAN; IRON CHELATION; IRON OVERLOAD; KNOWLEDGE; LONG TERM CARE; MEMORY; MONOTHERAPY; MOOD; MOTIVATION; NURSE; PAIN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PSYCHOLOGIST; QUALITY OF LIFE; REVIEW; SELF CONCEPT; SELF DISCLOSURE; SELF MONITORING; SOCIAL BEHAVIOR; STIGMA; SUBSTANCE ABUSE; THALASSEMIA MAJOR; TRAINING; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADOLESCENT; ANEMIA, SICKLE CELL; BENZOIC ACIDS; BETA-THALASSEMIA; CHILD; DEFEROXAMINE; DOSAGE FORMS; HUMANS; INFUSIONS, INTRAVENOUS; IRON CHELATING AGENTS; IRON OVERLOAD; PATIENT CARE TEAM; PATIENT COMPLIANCE; PYRIDONES; TIME FACTORS; TRIAZOLES;

EID: 84355166625     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-011-0927-3     Document Type: Review

References (40)

1. JA Cramer A Roy A Burrell, et al. 2008 Medication compliance and persistence: terminology and definitions Value Health 11 44 47 18237359 10.1111/j.1524-4733.2007.00213.x (Pubitemid 351160875)
2. World Health Organization. Adherence to long-term therapies. Evidence for action. 2003. http://www.who.int/chp/knowledge/publications/adherence-full- report.pdf.
3. ZI Cabantchik W Breuer G Zanninelli P Cianciulli 2005 LPI-labile plasma iron in iron overload Best Pract Res Clin Haematol 18 277 287 15737890 10.1016/j.beha.2004.10.003 1:CAS:528:DC%2BD2MXhvVSmtb0%3D (Pubitemid 40298370)
4. AV Hoffbrand A Cohen C Hershko 2003 Role of deferiprone in chelation therapy for transfusional iron overload Blood 102 17 24 12637334 10.1182/blood-2002-06-1867 1:CAS:528:DC%2BD3sXltFemtLw%3D (Pubitemid 36759630)
5. Ferriprox prescribing information. 2007. http://www.ferriprox.com.
6. ®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload Haematologica 91 873 880 16818273 1:CAS:528:DC%2BD28XnslSnu7c%3D (Pubitemid 44023139)
7. JB Porter 2001 Deferoxamine pharmacokinetics Semin Hematol 38 Suppl 1 63 68 11206963 10.1016/S0037-1963(01)90061-7 1:CAS:528:DC%2BD3MXhtVegsLk%3D (Pubitemid 32110273)
8. FN al Refaie LN Sheppard P Nortey, et al. 1995 Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload Br J Haematol 89 403 408 7873392 10.1111/j.1365-2141.1995.tb03318.x 1:CAS:528: DyaK2MXkvVSrur8%3D
9. S Daar A Pathare H Nick, et al. 2009 Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia Eur J Haematol 82 454 457 19191863 10.1111/j.1600-0609.2008.01204.x 1:CAS:528:DC%2BD1MXmtVyls7s%3D
10. GM Brittenham PM Griffith AW Nienhuis, et al. 1994 Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major N Engl J Med 331 567 573 8047080 10.1056/NEJM199409013310902 1:STN:280:DyaK2czit1yntQ%3D%3D (Pubitemid 24265698)
11. V Gabutti A Piga 1996 Results of long-term iron-chelating therapy Acta Haematol 95 26 36 8604584 10.1159/000203853 1:CAS:528:DyaK28XisFymurY%3D (Pubitemid 26071428)
12. B Modell M Khan M Darlison 2000 Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register Lancet 355 2051 2052 10885361 10.1016/S0140-6736(00)02357-6 1:STN:280:DC%2BD3czjvFyksg%3D%3D (Pubitemid 30339248)
13. C Borgna-Pignatti S Rugolotto P De Stefano, et al. 2004 Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine Haematologica 89 1187 1193 15477202 (Pubitemid 39390442)
14. D Matsui C Hermann J Klein, et al. 1994 Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator J Clin Pharmacol 34 944 949 7983239 1:STN:280: DyaK2M%2FnsVemug%3D%3D (Pubitemid 24321081)
15. JB Porter 2001 Practical management of iron overload Br J Haematol 115 239 252 11703317 10.1046/j.1365-2141.2001.03195.x 1:CAS:528:DC%2BD3MXptVyru7c%3D (Pubitemid 34203484)
16. TE Delea J Edelsberg O Sofrygin, et al. 2007 Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review Transfusion 47 1919 1929 17880620 10.1111/j.1537-2995.2007.01416.x 1:CAS:528:DC%2BD2sXht1elsrnN (Pubitemid 47438560)
17. Delea TE, Sofrygin O, Baladi J-F, Thomas SK, Phatak P, Coates TD. Costs and consequences of inadequate compliance with deferoxamine therapy in patients with transfusion-dependent thalassemia. Presented at International Society for Pharmaceutical and Outcomes Research (ISPOR), May 20-24, Philadelphia, PA 2006.
18. MD Cappellini 2005 Overcoming the challenge of patient compliance with iron chelation therapy Semin Hematol 42 S19 S21 15846581 10.1053/j.seminhematol. 2005.01.001 1:STN:280:DC%2BD2M3ht1WqsQ%3D%3D (Pubitemid 40410480)
19. KP Windebank JJ Spinetta 2008 Do as I say or die: compliance in adolescents with cancer Pediatr Blood Cancer 50 1099 1100 18360837 10.1002/pbc.21460 (Pubitemid 351500161)
20. A Maggio G D'Amico A Morabito, et al. 2002 Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial Blood Cells Mol Dis 28 196 208 12064916 10.1006/bcmd.2002.0510 (Pubitemid 34743754)
21. DJ Pennell V Berdoukas M Karagiorga, et al. 2006 Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis Blood 107 3738 3744 16352815 10.1182/blood-2005-07-2948 1:CAS:528:DC%2BD28Xkt1Giu7Y%3D
22. A Piga C Gaglioti E Fogliacco F Tricta 2003 Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis Haematologica 88 489 496 12745268 1:CAS:528:DC%2BD3sXlslCjurw%3D (Pubitemid 36648438)
23. R Fischer F Longo P Nielsen, et al. 2003 Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: application of SQUID biomagnetic liver susceptometry Br J Haematol 121 938 948 12786807 10.1046/j.1365-2141.2003.04297.x 1:CAS:528:DC%2BD3sXls1GntLY%3D (Pubitemid 36760315)
24. S Daar AV Pathare 2006 Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload Ann Hematol 85 315 319 16450126 10.1007/s00277-005-0075-z 1:CAS:528: DC%2BD28Xks1OktL8%3D (Pubitemid 43732654)
25. A El-Beshlawy C Manz M Naja, et al. 2008 Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience Ann Hematol 87 545 550 18351337 10.1007/s00277-008-0471-2 1:CAS:528:DC%2BD1cXmt12rurY%3D
26. CM Dezii 2000 A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension Manag Care 9 2 6 11729417 1:STN:280:DC%2BD3MnosVSntw%3D%3D
27. CM Dezii H Kawabata M Tran 2002 Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes South Med J 95 68 71 11827247 (Pubitemid 34131538)
28. F Trachtenberg E Vichinsky D Haines, et al. 2011 Iron chelation adherence to deferoxamine and deferasirox in thalassemia Am J Hematol 86 433 436 21523808 10.1002/ajh.21993
29. MD Cappellini M Bejaoui L Agaoglu, et al. 2007 Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia Clin Ther 29 909 917 17697909 10.1016/j.clinthera.2007.05.007 1:CAS:528:DC%2BD2sXotFymsL8%3D (Pubitemid 47241173)
30. ®, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis: substudy of a randomized open-label Phase II trial Acta Haematol 119 133 141 18408362 10.1159/000125550 1:CAS:528:DC%2BD1cXns1Siu74%3D (Pubitemid 351896547)
31. Garbowski M, Eleftheriou P, Pennell D et al. Impact of compliance, ferritin and LIC on long-term trends in myocardial T2*with deferasirox. Blood. 2008;112(11):abst 116.
32. M Evangeli K Mughal JB Porter 2010 Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review Hemoglobin 34 305 321 20524820 10.3109/03630269.2010.485080 1:CAS:528:DC%2BC3cXmvFyiu7g%3D
33. C Salzman 1995 Medication compliance in the elderly J Clin Psychiatry 56 Suppl 1 18 22 7836347
34. A Giagounidis PS di Leto S Ille P Fenaux 2011 A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS Ann Hematol 90 667 673 21327403 10.1007/s00277-011-1181-8
35. D Rofail L Abetz M Viala, et al. 2009 Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument Value Health 12 109 117 18637142 10.1111/j.1524-4733.2008.00390.x
36. E Jabbour G Garcia-Manero A Taher HM Kantarjian 2009 Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy Oncologist 14 489 496 19365094 10.1634/theoncologist.2008-0154 1:CAS:528:DC%2BD1MXnvVOlsbw%3D
37. MD Cappellini JB Porter A El-Beshlawy, et al. 2010 Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias Haematologica 95 557 566 19951979 10.3324/haematol.2009.014696 1:CAS:528:DC%2BC3cXhtlWjs7fP
38. N Gattermann C Finelli M Della Porta, et al. 2010 Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study Leuk Res 34 1143 1150 20451251 10.1016/j.leukres.2010.03.009 1:CAS:528:DC%2BC3cXps1Wluro%3D
39. KR Amico J Toro-Alfonso JD Fisher 2005 An empirical test of the information, motivation and behavioral skills model of antiretroviral therapy adherence AIDS Care 17 661 673 16036253 10.1080/09540120500038058 1:STN:280:DC%2BD2MznvVaguw%3D%3D (Pubitemid 41113004)
40. MJ Johnson 2002 The Medication Adherence Model: a guide for assessing medication taking Res Theory Nurs Pract 16 179 192 12472293 10.1891/rtnp.16.3. 179.53008